scholarly journals BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

2011 ◽  
Vol 104 (5) ◽  
pp. 856-862 ◽  
Author(s):  
T Yokota ◽  
T Ura ◽  
N Shibata ◽  
D Takahari ◽  
K Shitara ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Braf Mutation ◽  
Recurrent Colorectal Cancer

KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

2009 ◽  
Vol 27 (35) ◽  
pp. 5931-5937 ◽  
Author(s):  
Susan D. Richman ◽  
Matthew T. Seymour ◽  
Philip Chambers ◽  
Faye Elliott ◽  
Catherine L. Daly ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Braf Mutation ◽  
Poor Prognosis ◽  
Advanced Colorectal Cancer ◽  
Progression Free Survival ◽  
Predictive Biomarker ◽  
Poor Prognostic Factor ◽  
Minimal Impact ◽  
The Impact

PurposeActivating mutation of the KRAS oncogene is an established predictive biomarker for resistance to anti–epidermal growth factor receptor (anti-EGFR) therapies in advanced colorectal cancer (aCRC). We wanted to determine whether KRAS and/or BRAF mutation is also a predictive biomarker for other aCRC therapies.Patients and MethodsThe Medical Research Council Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing (MRC FOCUS) trial compared treatment sequences including first-line fluorouracil (FU), FU/irinotecan or FU/oxaliplatin in aCRC. Tumor blocks were obtained from 711 consenting patients. DNA was extracted and KRAS codons 12, 13, and 61 and BRAF codon 600 were assessed by pyrosequencing. Mutation (mut) status was assessed first as a prognostic factor and then as a predictive biomarker for the benefit of adding irinotecan or oxaliplatin to FU. The association of BRAF-mut with loss of MLH1 was assessed by immunohistochemistry.ResultsThree hundred eight (43.3%) of 711 patients had KRAS-mut and 56 (7.9%) of 711 had BRAF-mut. Mutation of KRAS, BRAF, or both was present in 360 (50.6%) of 711 patients. Mutation in either KRAS or BRAF was a poor prognostic factor for overall survival (OS; hazard ratio [HR], 1.40; 95% CI, 1.20 to 1.65; P < .0001) but had minimal impact on progression-free survival (PFS; HR, 1.16; 95% CI, 1.00 to 1.36; P = .05). Mutation status did not affect the impact of irinotecan or oxaliplatin on PFS or OS. BRAF-mut was weakly associated with loss of MLH1 staining (P = .012).ConclusionKRAS/BRAF mutation is associated with poor prognosis but is not a predictive biomarker for irinotecan or oxaliplatin. There is no evidence that patients with KRAS/BRAF mutated tumors are less likely to benefit from these standard chemotherapy agents.

KRAS AND BRAF mutation rates and survival outcomes in colorectal cancer in an ethnically-diverse cohort

Pathology ◽  
2021 ◽  
Vol 53 ◽  
pp. S59
Author(s):  
P. Habashy ◽  
K. Wilkinson ◽  
L. Kim ◽  
W. Ng ◽  
S. Lim ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Braf Mutation ◽  
Ethnically Diverse ◽  
Mutation Rates ◽  
Survival Outcomes

scholarly journals Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen

1999 ◽  
Vol 79 (3-4) ◽  
pp. 509-514 ◽  
Author(s):  
J N Primrose ◽  
H Bleiberg ◽  
F Daniel ◽  
S Van Belle ◽  
J L Mansi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Biological Activity ◽  
Carcinoembryonic Antigen ◽  
Recurrent Colorectal Cancer

scholarly journals Karyopherin alpha 2 expression is a novel diagnostic and prognostic factor for colorectal cancer

2017 ◽  
Vol 13 (3) ◽  
pp. 1194-1200 ◽  
Author(s):  
Lei Yu ◽  
Guiyu Wang ◽  
Qian Zhang ◽  
Li Gao ◽  
Rui Huang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor

PDGF-BB is a Novel Prognostic Factor in Colorectal Cancer

2008 ◽  
Vol 15 (8) ◽  
pp. 2129-2136 ◽  
Author(s):  
Yoshito Nakamura ◽  
Fumiaki Tanaka ◽  
Yasuji Yoshikawa ◽  
Koshi Mimori ◽  
Hiroshi Inoue ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor
Sign in / Sign up

Export Citation Format

Share Document